Alector, Inc. (ALEC)
- Previous Close
4.81 - Open
4.83 - Bid 5.22 x 200
- Ask 5.26 x 400
- Day's Range
4.83 - 5.29 - 52 Week Range
3.66 - 9.06 - Volume
448,590 - Avg. Volume
682,588 - Market Cap (intraday)
502.684M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.56 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.50
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
www.alector.comRecent News: ALEC
Performance Overview: ALEC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALEC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALEC
Valuation Measures
Market Cap
506.02M
Enterprise Value
-3.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.53
Price/Book (mrq)
3.77
Enterprise Value/Revenue
-0.04
Enterprise Value/EBITDA
0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-134.34%
Return on Assets (ttm)
-13.46%
Return on Equity (ttm)
-74.81%
Revenue (ttm)
97.06M
Net Income Avi to Common (ttm)
-130.39M
Diluted EPS (ttm)
-1.56
Balance Sheet and Cash Flow
Total Cash (mrq)
548.86M
Total Debt/Equity (mrq)
29.01%
Levered Free Cash Flow (ttm)
34.8M